Vorasidenib | Isocitrate dehydrogenase 1/2 inhibitor

Available Options

Size:PriceQuantity 
5 mg$75.00
25 mg$280.00
Request Quote / Bulk / Custom Size
Product Inquiry

Vorasidenib (1644545-52-7) is a highly potent (IC50’s = 7 nM IDH2-R140Q, 0.6 nM IDH1-R132H/WT, and 0.25 nM Neurosphere TS603 IDH1-R132H), selective, and brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2).1 It led to >97% inhibition of 2-hydroxyglutarate production in mIDH1 glioma tissue.  Vorasidenib significantly improved progression-free survival and delayed time to next intervention in a phase 3 glioma trial.2

References/Citations:

  1. Konteatis et al. (2020), Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma; ACS Med. Chem. Lett. 11 101
  2. Mellinghoff et al. (2023), Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma; N. Engl. J. Med. 389 589
1644545-52-7, AG-881, brain penetrant IDH inhibitor, IDH1 inhibitor, IDH1/2 inhibitor, IDH2 inhibitor, mutant IDH1 inhibitor, mutant IDH1/2 inhibitor, mutant IDH2 inhibitor, vorasidenib, Vorasidenib supplier
Alternate Name:
AG-881

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Vorasidenib (1644545-52-7) is a highly potent (IC50’s = 7 nM IDH2-R140Q, 0.6 nM IDH1-R132H/WT, and 0.25 nM Neurosphere TS603 IDH1-R132H), selective, and brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2).1 It led to >97% inhibition of 2-hydroxyglutarate production in mIDH1 glioma tissue.  Vorasidenib significantly improved progression-free survival and delayed time to next intervention in a phase 3 glioma trial.2

References/Citations:

  1. Konteatis et al. (2020), Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma; ACS Med. Chem. Lett. 11 101
  2. Mellinghoff et al. (2023), Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma; N. Engl. J. Med. 389 589